Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy SalesZacks Investment Research • 02/27/25
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 02/26/25
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 02/26/25
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'Market Watch • 02/18/25
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a TurnaroundZacks Investment Research • 02/17/25
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit FacilityBusiness Wire • 02/14/25
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial ResultsBusiness Wire • 02/12/25
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta TherapeuticsBusiness Wire • 02/10/25
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYSBusiness Wire • 01/27/25
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product RevenueBusiness Wire • 01/13/25
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/25
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular DisorderZacks Investment Research • 12/19/24
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4Business Wire • 12/18/24
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025Zacks Investment Research • 12/17/24
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believeProactive Investors • 12/13/24
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?Zacks Investment Research • 12/13/24